ClinicalTrials.gg
Active, not recruitingNCT02768363Updated Oct 2, 2026

Randomized Controlled Trial of CAN-2409 Immunotherapy During Active Surveillance for Prostate Cancer (ULYSSES)

A Phase 2 interventional study of aglatimagene besadenovec and placebo in Prostate Cancer, sponsored by Candel Therapeutics, Inc.. Active, not recruiting at 23 sites in 2 countries. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-02.

Sponsored by Candel Therapeutics, Inc. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
187
Allocation
Randomized
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 3,596 studies in Prostatic Neoplasms with a site in United States — 608 open to participants now, 977 under way, 101 of them phase 3. Prostatic Neoplasms · United States.

Enrollment
582nd of 3,023
187 · median 48
Started
2016
with 136 others
Phase 2
1,063 of 3,596
145 open now
Primary completion
2024-11
later than 82 of 971 live
Registered
1,900th of 3,596
by date

Among the 3,596 studies in Prostatic Neoplasms with a site in United States, this one is the 582nd largest by enrollment of the 3,023 interventional ones that give a count, is one of 137 that started in 2016, is one of 1,063 in phase 2, reaches primary completion later than 82 of the 971 other live ones, and was the 1,900th registered.

Prostatic Neoplasms

7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

608 of the 3,596 studies in Prostatic Neoplasms with a site in United States are open now. Recruiting first, the newest first:

603 more — sign in →

All 608 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 1,230 Prostatic Neoplasms studies recruiting now, 929 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 3,596 studies in Prostatic Neoplasms with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the effectiveness of CAN-2409 immunotherapy in patients undergoing active surveillance for localized prostate cancer. CAN-2409 involves the use of aglatimagene besadenovec to kill tumor cells and stimulate a cancer vaccine effect. Killing tumor cells in an immune stimulatory environment induces the body's immune system to detect and destroy cancer cells. CAN-2409 has been well tolerated in previous trials in patients with prostate cancer and other tumor types. Biochemical, pathologic and immune responses have been demonstrated in newly diagnosed and recurrent prostate cancer. The hypothesis is that CAN-2409 can lead to improvement in the clinical outcome for patients with prostate cancer. Participants will be randomized to the CAN-2409 or control arm at a 2:1 ratio. Both arms receive standard of care active surveillance evaluations.

03

Conditions studied

  • Prostate Cancer

Browse trials for

Keywords

  • Immunotherapy
  • Tumor vaccine
  • Immuno-oncology
  • Cytotoxicity
  • Prostate cancer
  • Active Surveillance
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • confirmed adenocarcinoma of the prostate
  • Patients choosing active surveillance
  • Patients meeting definition of NCCN low risk, intermediate risk OR patients having only one NCCN high-risk feature

    • NCCN Low Risk is defined as having all of the following: PSA \< 10 ng/ml, Gleason ≤ 6, T1-T2a
    • NCCN Intermediate Risk is defined as having at least one of the following and no high risk features: PSA 10-20 ng/ml, Gleason score =7, T2b-T2c
    • High Risk with a single high risk feature is defined as having only one of the following: PSA>20 ng/ml, Gleason score 8-10, or T3a
    • Excluded are those in the following risk groups: High risk with more than 1 high risk factor; Locally advanced/very high risk=T3b-T4; : N1 or M1
  • Patients must be planning and medically able to tolerate multiple transrectal ultrasound guided injections.
  • Performance status 0-2

Exclusion criteria

Exclusion Criteria include:

  • Active liver disease, including known cirrhosis or active hepatitis
  • Patients on systemic (>10 mg prednisone per day) or other drugs
  • Known + patients
  • Regional lymph node involvement or distant
  • Other current (except squamous or basal cell skin cancers)
  • Other serious co-morbid illness or compromised organ function that, in the opinion of the investigator, would interfere with treatment or follow up
  • Prior treatment for prostate cancer except TURP. If prior TURP, patients must be deemed able to receive prostate and multiple intra-prostatic injections by the investigator
  • Patients taking 5-alpha-reductase inhibitors (e.g. finasteride, dutasteride)
  • Patients who had or plan to use ADT or have history of an orchiectomy.
  • Patients who are planning to undergo radical treatment for prostate cancer within 12 months.
  • Known sensitivity or allergic reactions to acyclovir or valacyclovir
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
187 participants (actual)

Study arms

  • Active comparator
    CAN-2409

    Patients randomized to the active arm will receive two courses of aglatimagene besadenovec (CAN-2409) + valacyclovir

    Biological: aglatimagene besadenovec · Drug: valacyclovir

  • Placebo comparator
    Placebo

    Patients randomized to the placebo arm will receive two corresponding courses of placebo + valacyclovir

    Biological: placebo · Drug: valacyclovir

Interventions

  • Aglatimagene besadenovec will be delivered to the prostate via trans-rectal ultrasound guided injection followed by 14 days of oral prodrug, valacyclovir. The second aglatimagene besadenovec injection will be 2-3 weeks after the first followed by 14 days of valacyclovir.

    Also known as: AdV-tk, CAN-2409

  • Biologicalplacebo

    Placebo will be delivered to the prostate via trans-rectal ultrasound guided injection followed by 14 days of oral prodrug, valacyclovir. The second placebo injection will be 2-3 weeks after the first followed by 14 days of valacyclovir.

  • Oral prodrug to be given for 14 days starting the day after each aglatimagene besadenovec or placebo injection.

06

What researchers measure

Primary outcomes

  1. Progression-free survival (PFS)

    Progression-free survival is defined as the time from randomization to evidence of histological disease progression or death due to prostate cancer

    Time frame: Baseline to study completion, approximately 5 years

Secondary outcomes

  1. Negative biopsy rate at 1-year landmark

    Time frame: 1 year

  2. Percentage of patients with adverse events

    Time frame: 30 days after last dose of study drug

07

Study locations

23 sites
  • Foothills Urology
    Golden, Colorado 80401, United States
  • Jesse Brown VA Medical Center
    Chicago, Illinois 60612, United States
  • The University of Chicago
    Chicago, Illinois 60637, United States
  • Southeast Louisiana Veterans Health Care System
    New Orleans, Louisiana 70119, United States
  • Walter Reed National Military Medical Center
    Bethesda, Maryland 20889, United States
  • Kansas City VA Medical Center
    Kansas City, Missouri 64128, United States
  • Sierra Nevada Health Care System VA
    Reno, Nevada 89502, United States
  • Hackensack University Medical Center
    Hackensack, New Jersey 07601, United States
  • Advanced Radiation Centers of New York (Integrated Medical Professionals)
    North Hills, New York 11042, United States
  • Associated Medical Professionals of NY, PLLC
    Syracuse, New York 13210, United States
  • Southwest Urology, Clinical Research Solutions
    Middleburg Heights, Ohio 44130, United States
  • Oklahoma City VA Healthcare System
    Oklahoma City, Oklahoma 73104, United States
  • VA Portland Health Care System
    Portland, Oregon 97239, United States
  • Oregon Urology Insitute
    Springfield, Oregon 97477, United States
  • Lancaster Urology
    Lancaster, Pennsylvania 17604, United States
  • Allegheny Health Network-Triangle Urological Group
    Pittsburgh, Pennsylvania 15212, United States
  • Ralph H. Johnson Veterans Affairs Medical Center
    Charleston, South Carolina 29401, United States
  • San Antonio VA Healthcare System
    San Antonio, Texas 78229-4404, United States
  • Woodland Center
    The Woodlands, Texas 77384, United States
  • Texas Urology Specialists
    Tomball, Texas 77375, United States
  • Hunter Holmes McGuire VA Medical Center
    Richmond, Virginia 23249, United States
  • Salem VA Medical Center
    Salem, Virginia 24153, United States
  • Instituto Nacional de Ciencias Medicas y Nutrición, Salvador Subirán
    Mexico City, Mexico
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2016, a primary completion of Nov 2024 and a completion of Dec 2026. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
May 6, 2016
First posted
May 11, 2016
Start
May 2016
Primary completionActual
Nov 2024
CompletionEst.
Dec 2026
Results delay requested
Jul 28, 2025
Last update
Oct 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date
1 update, last Oct 2, 2026
Show all 1 update
  1. Oct 2, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT02768363
Lead sponsor
Candel Therapeutics, Inc.
Responsible party
Sponsor
First posted
May 11, 2016
Start date
May 2016
Primary completion
Nov 2024
Completion
Dec 2026 (estimated)
Last update
Oct 2, 2026

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Aglatimagene besadenovec

Start the discussion